

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an Envelope addressed to: Mail Stop Disclosure Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on:

Date: 9/13/06

By: [Signature]  
Winsome A. St. Rose

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:	)
Martin Dugas, et al.	) EXAMINER: Unassigned
SERIAL NO.: 10/575,805	) ART UNIT: Unassigned
PCT FILING DATE: NOVEMBER 4, 2004	) Confirmation No. 3903
FOR: METHOD FOR DISTINGUISHING	) DOCKET NO 223291-US
T(11Q23)/MLL-POSITIVE	
LEUKEMIAS FROM T(11Q23)/MLL	
NEGATIVE LEUKEMIA	

INFORMATION DISCLOSURE STATEMENT

Mail Stop Disclosure.  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicant submits herewith a Form-1449, in compliance with the duty of disclosure requirements of 37 C.F.R. §1.56, 1.97 and 1.98, listing accompanying documents that may be considered material to the examination of this application. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits, whichever event occurs last. No certification or fee is therefore required under 37 C.F.R. § 1.97(b). However, should the Commissioner determine that fees are due in order for the Information Disclosure Statement to be considered at this stage, the Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to Deposit Account No. 50-0812.


Applicants wish to provide the USPTO with an electronic copy of WO 03/039433A2, which is in excess of 2,900 pages.

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested.

Respectfully submitted,


Date: 2/12/06

  
Robert W. Mann  
Reg. No. 48,555

Correspondence Address:

Roche Molecular Systems, Inc  
1145 Atlantic Avenue  
Alameda, CA 94501  
Tele: (510) 814-2800  
Fax: (510) 814-2973

U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 22329-US	Serial No. 10/575,805
<b>LIST OF INFORMATION CITED BY APPLICANT</b> (Use several sheets if necessary)		Applicant: Martin Dugas, et al	
		International Filing Date: November 4, 2004	Group



### U.S. PATENT DOCUMENTS

* EXAMINER INITIAL		DOCUMENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	1	5,210,015	05/11/93	Gelfand, et al	435	6	08/06/90
	2	5,445,934	08/29/95	Fodor, et al	435	6	09/30/92
	3	5,487,972	01/30/96	Gelfand, et al	435	6	01/05/93
	4	5,700,637	12/23/97	E. Southern	435	6	04/19/94
	5	5,744,305	04/28/98	Fodor, et al	435	6	06/06/95
	6	5,804,375	09/08/98	Gelfand, et al	435	6	04/25/95
	7	5,945,334	08/31/99	Besemer, et al	435	287.2	06/07/95
	8	6,174,670 B1	01/16/01	Wittwer, et al	435	6	06/04/97
	9	2003/0138793 A1	07/24/03	Su, et al	435	6	06/10/02

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	10	0 373 203 B1	08/31/94	EP			
	11	0 619 321 B1	01/07/90	EP			
	12	1 043 676 A1	10/11/00	EP			
	13	WO 92/02638	02/20/92	PCT			
	14	WO 03/039443 A2	05/15/03	PCT			
	15	WO 03/083140 A3	10/9/03	PCT			
	16	WO 2005/045435	05/19/05	PCT			
	17	EP2004/012462 PCT Search Report	06/09/2005	PCT			

### OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	18	Alizadeh, A., et al., 1999, "The Lymphochip: A Specialized cDNA Microarray for the Genomic-scale Analysis of Gene Expression in Normal and Malignant Lymphocytes", Cold Springs Harbor Symposium on Quantitative Biology, Volume LXIV, Cold Springs Harbor Laboratory Press, pp 71-78
	19	Armstrong, S., et al, 2002, "MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia", <i>Nature Genetics</i> , 30:41-47
	20	Armstrong, S., et al, 2003, "MLL - Rearranged Leukemias: Insights From Gene Expression Profiling", <i>Seminars in Hematology</i> , 40(4):268-273
	21	Brown, M., et al, 2000, "Knowledge-based analysis of microarray gene expression data by using support vector machines", <i>PNAS</i> , 97(1):262-267
	22	Dugas, M., et al., 2001, "A comprehensive leukemia database: integration of cytogenetics, molecular genetics and microarray data with clinical information, cytomorphology and immunophenotyping", <i>Leukemia</i> , 15:1805-1810

	23	Dugas, M., et al., 2002, "Impact of Integrating Clinical and Genetic Information", <i>In Silico Biology</i> , 2:383-391
	24	Furey, T., et al., 2000, "Support vector machine classification and validation of cancer tissue samples using microarray expression data", <i>Bioinformatics</i> , 16(10):906-914
	25	Golub, T., et al, 1999, "Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring", <i>Science</i> , 286:531-537
	26	Haferlach, T., et al., "Abstract: The Diagnosis of 14 Specific Subtypes of Leukemia Is Possible Based on Gene Expression Profiles: A Study on 263 Patients with AML, ALL, CML, or CLL", <i>Blood</i> , 100, Abstract 523
	27	Harlow, E., et al, 1988, "Antibodies A Laboratory Manual", <i>Cold Spring Harbor Laboratory</i>
	28	Koehler, G., et al., 1975, "Continuous cultures of fused cells secreting antibody of predefined specificity", <i>Nature</i> . 256:495-497
	29	Kohlmann, A., et al., 2002, "Abstract: A Simplified and Partially Automated target Preparation Method for Gene Expression Profiling", <i>Blood</i> , 100, Abstract 4287
	30	Kohlmann, A., et al., 2002, "Abstract:: A Gene Expression Study of 59 Acute Myeloid Leukemia (AML) Patients with recurrent Cytogenetic Abnormalities", <i>Blood</i> , 100, Abstract 1205
	31	Kohlmann, A., et al., 2003, "Molecular Characterization of Acute Leukemias by Use of Microarray Technology", <i>Genes, Chromosomes &amp; Cancer</i> , 37:396-405
	32	Liu, G., et al., 2003, "NetAffx: Affymetrix probesets and annotations", <i>Nucleic Acids Research</i> , 31(1):82-86
	33	Mosquera-Caro, M., et al., 2002, "Abstract: Heterogeneity of Gene Expression Profiles in MLL-Associated Infant Leukemia: Identification of Distinct Expression Profiles and Novel Therapeutic Targets for Each MLL Translocation Variant", <i>Blood</i> , 100, Abstract 2943
	34	Rozovskaia, T., et al., 2001, "Upregulation of <i>Meis1</i> and <i>HoxA9</i> in acute lymphocytic leukemias with the t(4:11) abnormality", <i>Oncogene</i> , 20:874-878
	35	Sambrook, J., et al., 1989, "Molecular Cloning A Laboratory Manual Second Edition", <i>Cold Spring harbor Laboratory Press</i> ,
	36	Schoch, C., et al., 2003, "AML with 11q23/MLL abnormalities as defined by the WHO Classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases", <i>Blood</i> , 102(7):2395-23402
	37	Storey, J., et al., 2003, "Statistical significance for genomewide studies," <i>PNAS</i> , 100(16):9440-9445
	38	Tsutsumi, S., et al., 2001, "Two distinct gene expression signatures in pediatric acute lymphoblastic leukemia with MLL rearrangements," <i>Cancer Research</i> , 63:4882-4887
EXAMINER		DATE CONSIDERED
*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		